Xintela appoints Sven Kili as Chief Operating Officer
Lund, Sweden, 16 April 2019 – Sven Kili, an Executive Director and the Chief Medical Officer of Xintela, extends his commitment by taking on the Chief Operating Officer (COO) role. Sven Kili is a surgeon and specialist in orthopedics and, through leading positions in pharmaceutical companies including Genzyme, Sanofi, and GSK, has many years’ experience […]
SVEN KILI TAKES ROLE AS CHIEF MEDICAL OFFICER IN XINTELA
Lund, Sweden, August 29, 2018 – Xintela AB (publ) announces today that Sven Kili extends his commitment to Xintela as Chief Medical Officer (CMO). Sven Kili, a board member and consultant to Xintela, extends his commitment to Xintela as CMO on a consultancy basis. Sven is a physician and specialist in orthopedics and, through leading […]
Keld Søndergaard leaves Xintela’s Board of Directors
Xintela AB (publ) announces that Keld Søndergaard has resigned from the company’s Board of Directors, citing personal reasons. Xintela’s larger shareholders, acting as an informal nomination committee, will consider potential replacement candidates to propose to the next Annual General Meeting. Keld Søndergaard was elected as a new member of the Board at the Annual General […]
Xintela recruits Liselotte Theorell as Director Product Development and Quality Management
Xintela AB (publ) announces that the company has recruited Liselotte Theorell as Director Product Development and Quality Management. The recruitment is an important step towards the production of stem cells under GMP (Good Manufacturing Practice) for upcoming clinical studies. “Liselotte is one of few persons in Sweden who possess such extensive competence in quality management […]
Keld Søndergaard nominated as new board member
The Board of Xintela AB (publ) announces that Keld Søndergaard has been nominated for election as a new member of the Board at the annual general meeting on the 18th of May 2017. Also proposed for re-election are Greg Batcheller, Karin Wingstrand, Sven Kili and Claes Post. The proposal is supported by shareholders who represent […]
